Cervical CancerPETCVOCCNCT07325682
Diagnostic Evaluation of Viral Persistence in Cervical Cancer
A study testing Electroacupuncture in people with Cervical Cancer, run by Oncology Center,Ministry Of Heath,Uzbekistan at 1 site in Uzbekistan.
Trial summary
This study aims to evaluate the diagnostic value of an electroacupuncture-based method for detecting viral persistence (human papillomavirus and SARS-CoV-2) in patients with cervical cancer. Read more about this study
- Who is it for?
- Ages 21 to 70 years, women only
- Conditions the study is for
- Cervical Cancer
- What is being tested?
- Electroacupuncture
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUzbekistan
- Study dates
- 30 Apr 2025to 30 Dec 2030
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 70 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed cervical cancer (FIGO stage IIIA-IVA)
- Age ≥21 years
- ECOG performance status adequate for diagnostic procedures
- Adequate organ function
- Ability to provide informed consent
Who cannot join
- Poor renal function (elevated creatinine)
- Significant liver dysfunction (elevated bilirubin or liver enzymes)
- Severe cardiovascular or pulmonary disease
- Pregnancy or breastfeeding
- Severe mental illness or inability to provide informed consent
- Known non-compliance or substance abuse
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Uzbekistan1 site
Regional Branch of the National Oncology and Radiology Center
Tashkent, 100154
About this study
Official title: Personalized, Scientifically Based Technologies in the Diagnosis and Treatment of SARS-CoV-2 as a Possible Cervical Cancer Risk Factor
This study aims to evaluate the diagnostic value of an electroacupuncture-based method for detecting viral persistence (human papillomavirus and SARS-CoV-2) in patients with cervical cancer. The study investigates whether persistent viral signatures can be identified through measurable electrodiagnostic responses at acupuncture points associated with organ systems affected by chronic viral infection. The goal is to assess the feasibility, reproducibility, and potential clinical relevance of this diagnostic approach in oncology patients.
Read the detailed description
This study investigates the diagnostic potential of an electroacupuncture-based measurement method to detect viral persistence in patients with cervical cancer. Increasing evidence indicates that oncologic processes may be influenced by chronic viral activity, including persistent human papillomavirus (HPV) infection and, in some cases, secondary viral signatures such as SARS-CoV-2. Although HPV is the primary etiologic agent in cervical cancer, clinical observations suggest that long-term viral presence may contribute to variations in disease behavior, immune dysfunction, and treatment response.
The diagnostic method used in this study is based on measurement of electrical parameters at standardized acupuncture points. These points are functionally connected to organ systems involved in chronic viral disease. Changes in their electrical characteristics may reflect physiological responses associated with viral persistence. The technique has been previously developed and refined in clinical practice and has demonstrated reproducibility in identifying characteristic response patterns in patients with viral and post-viral conditions.
This study aims to evaluate whether measurable electrodiagnostic responses correlate with persistent viral signatures in cervical cancer patients. All participants undergo standardized diagnostic measurements performed under controlled conditions. The study does not involve therapeutic intervention, drug administration, or device implantation. Only diagnostic data are collected.
The primary objective is to assess whether this method can reliably identify patterns consistent with viral persistence. Secondary objectives include evaluating repeatability of measurements, describing characteristic profiles in this patient population, and assessing feasibility of integrating this diagnostic approach into clinical oncology settings.
This research is expected to contribute to a better understanding of viral involvement in cancer microenvironments and to support the development of non-invasive diagnostic tools for evaluating viral activity in oncologic patients.
- Conditions
- Cervical Cancer
- Being tested
- Electroacupuncture
- Keywords
- medicament testing, viral antigen persistance, Human Papillomavirus
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ElectroacupunctureDiagnostic test
Non-invasive electrodiagnostic assessment using electroacupuncture measurements to evaluate bioelectrical response patterns associated with viral markers in patients with cervical cancer.
| Study group | Role | What they receive |
|---|---|---|
| Diagnostic Group | Experimental | Non-invasive diagnostic method assessing bioelectrical response patterns associated with viral markers in patients with cervical cancer. Receives: Diagnostic Test: Electroacupuncture |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Bioelectrical Patterns Consistent With Viral Antigen Persistence
Diagnostic assessment to identify bioelectrical response patterns associated with viral antigen persistence in cervical cancer patients using a non-invasive bioelectrical testing approach.
Measured: At enrollment (single diagnostic session)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2026
- Study start30 Apr 2025
- Primary completion30 Jun 2030 (estimated)
- Study completion30 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oncology Center,Ministry Of Heath,Uzbekistan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Naylya Djumaeva, Oncology Center,Ministry Of Heath,Uzbekistan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07325682
- Sponsor's protocol ID
- CC-DIAG-001
- Acronym
- PETCVOCC
- Status last verified
- Oct 2026
- First submitted
- 9 Dec 2025
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared because the study involves a small diagnostic cohort and contains sensitive clinical information that cannot be anonymized to a level ensuring full participant privacy. The data will be used only for internal scientific analysis within the approved protocol.